Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Newest Articles
    • Current Issue
    • Methods & Resources
    • Archive
    • Subjects
  • Collections
  • Submit
    • Submit a Manuscript
    • Author Guidelines
    • License, Copyright, Fee
    • FAQ
    • Why submit
  • About
    • About Us
    • Editors & Staff
    • Board Members
    • Licensing and Reuse
    • Reviewer Guidelines
    • Privacy Policy
    • Advertise
    • Contact Us
    • LSA LLC
  • Alerts
  • Other Publications
    • EMBO Press
    • The EMBO Journal
    • EMBO reports
    • EMBO Molecular Medicine
    • Molecular Systems Biology
    • Rockefeller University Press
    • Journal of Cell Biology
    • Journal of Experimental Medicine
    • Journal of General Physiology
    • Cold Spring Harbor Laboratory Press
    • Genes & Development
    • Genome Research

User menu

  • My alerts

Search

  • Advanced search
Life Science Alliance
  • Other Publications
    • EMBO Press
    • The EMBO Journal
    • EMBO reports
    • EMBO Molecular Medicine
    • Molecular Systems Biology
    • Rockefeller University Press
    • Journal of Cell Biology
    • Journal of Experimental Medicine
    • Journal of General Physiology
    • Cold Spring Harbor Laboratory Press
    • Genes & Development
    • Genome Research
  • My alerts
Life Science Alliance

Advanced Search

  • Home
  • Articles
    • Newest Articles
    • Current Issue
    • Methods & Resources
    • Archive
    • Subjects
  • Collections
  • Submit
    • Submit a Manuscript
    • Author Guidelines
    • License, Copyright, Fee
    • FAQ
    • Why submit
  • About
    • About Us
    • Editors & Staff
    • Board Members
    • Licensing and Reuse
    • Reviewer Guidelines
    • Privacy Policy
    • Advertise
    • Contact Us
    • LSA LLC
  • Alerts
  • Follow lsa Template on Twitter
Research Article
Transparent Process
Open Access

Cell-free expression of the outer membrane protein OprF of Pseudomonas aeruginosa for vaccine purposes

View ORCID ProfileGéraldine Mayeux, Landry Gayet, Lavinia Liguori, Marine Odier, Donald K Martin, Sandra Cortès, View ORCID ProfileBéatrice Schaack, View ORCID ProfileJean-Luc Lenormand  Correspondence email
Géraldine Mayeux
1TheREx and Synabi, University Grenoble Alpes, CNRS, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble Institut Polytechnique (INP), Translational Innovation in Medicine and Complexity (TIMC), Grenoble, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Géraldine Mayeux
Landry Gayet
1TheREx and Synabi, University Grenoble Alpes, CNRS, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble Institut Polytechnique (INP), Translational Innovation in Medicine and Complexity (TIMC), Grenoble, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lavinia Liguori
1TheREx and Synabi, University Grenoble Alpes, CNRS, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble Institut Polytechnique (INP), Translational Innovation in Medicine and Complexity (TIMC), Grenoble, France
2Maison Familiale Rurale Moirans, Moirans, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marine Odier
1TheREx and Synabi, University Grenoble Alpes, CNRS, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble Institut Polytechnique (INP), Translational Innovation in Medicine and Complexity (TIMC), Grenoble, France
3Catalent Pharma Solutions, Eberbach, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donald K Martin
1TheREx and Synabi, University Grenoble Alpes, CNRS, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble Institut Polytechnique (INP), Translational Innovation in Medicine and Complexity (TIMC), Grenoble, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandra Cortès
4Synthelis, La Tronche, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Béatrice Schaack
1TheREx and Synabi, University Grenoble Alpes, CNRS, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble Institut Polytechnique (INP), Translational Innovation in Medicine and Complexity (TIMC), Grenoble, France
5University Grenoble Alpes, Commissariat à l’Énergie Atomique et aux Énergies Alternatives (CEA), CNRS, Institut de Biologie Structurale (IBS), Grenoble, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Béatrice Schaack
Jean-Luc Lenormand
1TheREx and Synabi, University Grenoble Alpes, CNRS, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble Institut Polytechnique (INP), Translational Innovation in Medicine and Complexity (TIMC), Grenoble, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jean-Luc Lenormand
  • For correspondence: jllenormand@chu-grenoble.fr
Published 10 May 2021. DOI: 10.26508/lsa.202000958
  • Article
  • Figures & Data
  • Info
  • Metrics
  • Reviewer Comments
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1. Production and purification of recombinant OprF proteoliposomes.

    (A) Comparison, using anti-His Western blot analysis, of cell-free OprF expression in the presence of liposomes of six different lipid compositions (LC 1 to LC 3′) 3 and 5 μl of each cell-free reaction mixture were analyzed. Anti-His antibody was conjugated to HRP and was detected using chemiluminescence. (B) Comparison, using anti-His Western blot analysis, of the influence of liposome concentration on OprF expression for each LC. (C) Purification of OprF proteoliposomes (LC 1) by sucrose gradient. Anti-His Western blot analysis of each 1 ml layer of the sucrose gradient (10 lanes from 0 to 40% sucrose), with OprF monomeric and oligomeric forms indicated (only dimeric, trimeric, and tetrameric forms are visible). (D) Evaluation, using Coomassie gel, of the purity of OprF proteoliposomes after purification by sucrose gradient and subsequent pellet washing with NaCl. (E) Trypsin digestion of OprF proteoliposomes after purification. The digested bands were revealed by Western blotting using an anti-his antibody.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2. Determination of OprF orientation in proteoliposomes by atomic force microscopy.

    (A, B, C) Atomic force microscopy topographic images of an OprF proteoliposomes’ sample absorbed on mica surface, acquired using a tip functionalized with Tris–NTA, without (A, B) and with Triton X-100 (C). The circles in white dotted lines correspond to proteoliposomes. (A′, B′, C′) Corresponding adhesion maps of specific adhesion forces between the Tris–NTA modified tip and OprF His-tag, without (A′, B′) and with Triton X-100 (C′). The white to grey squares represent values of adhesion forces between 80 and 150 pN, as illustrated by the scale bar on the right. The circles in white dotted lines corresponding to proteoliposomes are zoomed on the right. The white arrows indicate specific adhesion points validated by the force distance curves and correspond to 16 transmembrane passages based on the theoretical model Worm-Like Chain.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3. Determination of the membrane topology of OprF in liposomes by trypsin digestion.

    The result of the trypsin digestion of OprF at different incubation times is visualized by anti-His Western blot (FL, full length). Anti-His antibody was conjugated to HRP and was detected using chemiluminescence.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4. Detection of two transmembrane topologies adopted by OprF in proteoliposomes by Atomic Force Microscopy.

    (A, B) Force distance curves, obtained with a tip functionalized with Tris–NTA in Triton X-100 solution, detecting 64% of specific adhesion events corresponding to eight transmembrane domains (A) and 36% of specific adhesion events corresponding to 16 transmembrane domains (B), based on the theoretical model Worm-Like Chain.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5. Superimposition of circular dichroism spectra of OprF proteoliposomes before (black curve) and after addition of IFN-γ (red curve).
  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6. Visualization of liposomal surface by negative-staining (NS) EM. Scale bar 100 nm.

    (A) EM image of empty liposomes (incubated using the cell-free cell lysate and reaction mixture = negative control). (B, C, D, E) EM images of OprF proteoliposomes (LC1). The membrane was perforated with a series of holes with an average size of 9.5 ± 4 nm corresponding to OprF pores.

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7. Visualization of OprF pore-forming activity by Atomic Force Microscopy.

    (A) Topographic image of the surface of an OprF proteoliposome absorbed onto a freshly cleaved mica support, acquired using a tip functionalized with Tris–NTA, in presence of Triton X-100. (B) Corresponding adhesion map of specific adhesion forces between the tris–NTA modified tip and OprF His-tag. The white to grey squares represent adhesion forces values between 80 and 150 pN, as illustrated by the scale bar on the right. The circles in white dotted lines highlight pores. (C) Force distance curves detecting specific adhesion events (indicated by arrows).

  • Figure S1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S1. Measurements of OprF channel activity using impedance spectrometry and effect of IFN-γ.

    (A) Conductance of the t-BLM after the insertion of OprF proteoliposomes (blue squares) and empty liposomes (green triangles) for different KCl concentrations (150, 200, 300, 400, 500, 750 mM, and 1M), in 50 mM Tris pH 7.5. (B) Effects of increasing concentrations of IFN-γ (0–1.5 μM) on the conductance of the tBLM after incorporation of OprF (blue diamonds) and empty liposomes (orange squares) in 50 mM Tris, pH 7.5, 150 mM KCl. The conductance values correspond to the mean (±SD) of three values measured during 10 min. (A) and (B) are two separated experiments.

  • Figure 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 8. Immunization with recombinant OprF proteoliposomes protects mice against a bacterial challenge.

    (A) C57Bl/6 mice were immunized subcutaneously with 25, 50 or 75 μg of OprF in proteoliposome. 1 wk after the fourth immunization, OprF-immunized groups (n = 10 or 11) or control group (n = 11) were subcutaneously challenged with a lethal dosage of Pseudomonas aeruginosa CHA strain (2 × 107 CFU/mouse) and monitored for survival and disease symptoms for up to 80 h. (B) Naïve mice were subcutaneously challenged with a lethal dose of the CHA strain and an intraperitoneal injection with sera containing polyclonal antibodies induced by the OprF proteoliposomes was performed 1 h after the bacterial challenge. Mice were monitored for survival and disease symptoms for up to 80 h.

  • Figure S2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S2. Additional immunization with recombinant OprF proteoliposomes protects mice against a bacterial challenge.

    C57Bl/6 mice were immunized subcutaneously with 25, 50, or 75 μg of OprF in proteoliposome. 1 wk after the fourth immunization, OprF-immunized groups (n = 5 or 6) or control group (n = 6) were subcutaneously challenged with lethal dosage of Pseudomonas aeruginosa CHA strain (2 × 107 CFU/mouse) and monitored for survival and disease symptoms for up to 60 h.

  • Figure 9.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 9. Anti-OprF antibody titration curves of sera from immunized mice.

    Antibody titration curves of sera from mice immunized four times with 25, 50, or 75 μg of recombinant OprF proteoliposome. Control mice were immunized with liposomes previously incubated with cell-free lysate. Values are means of three mice per group determined by indirect ELISA using recombinant OprF proteoliposome as coated antigen.

  • Figure 10.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 10. Western blot illustrating the binding of both endogenous and recombinant OprF by polyclonal antibodies found in sera from immunized mice.

    GFP was used as a negative control. The secondary antibody binding polyclonal antibodies was an HRP-conjugated rabbit anti-mouse IgG and it was detected using chemiluminescence.

  • Figure 11.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 11.

    Analysis of the OprF proteoliposomes at different temperatures. (A, B) Evaluation of OprF stability in liposomes before (clt, control) and after 14 d storage at RT, 4°C, −20°C, and −80°C using Coomassie gel—SDS–PAGE (A) and anti-HIS Western blot analysis (B). The anti-His antibody was conjugated to HRP and was detected using chemiluminescence.

Tables

  • Figures
    • View popup
    Table 1.

    Content of the different lipid compositions.

    Lipid composition (LC)LipidsMolar ratio
    1Cholesterol2-4-2-2
    1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC)
    1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)
    1,2-dimyristoyl-sn-glycero-3-phosphate (sodium salt) (DMPA)
    1′LC1 + 1 mg/ml monophosphoryl lipid A (MPLA)
    21-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE)6-2-2
    1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (sodium salt) (POPG)
    E. coli cardiolipin (CL)
    2′LC2 + 1 mg/ml MPLA
    3POPE, POPG, E. coli CL, DMPA6-2-1-1
    3′LC3 + 1 mg/ml MPLA
PreviousNext
Back to top
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Life Science Alliance.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cell-free expression of the outer membrane protein OprF of Pseudomonas aeruginosa for vaccine purposes
(Your Name) has sent you a message from Life Science Alliance
(Your Name) thought you would like to see the Life Science Alliance web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OprF proteoliposome: a vaccine candidate
Géraldine Mayeux, Landry Gayet, Lavinia Liguori, Marine Odier, Donald K Martin, Sandra Cortès, Béatrice Schaack, Jean-Luc Lenormand
Life Science Alliance May 2021, 4 (6) e202000958; DOI: 10.26508/lsa.202000958

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
OprF proteoliposome: a vaccine candidate
Géraldine Mayeux, Landry Gayet, Lavinia Liguori, Marine Odier, Donald K Martin, Sandra Cortès, Béatrice Schaack, Jean-Luc Lenormand
Life Science Alliance May 2021, 4 (6) e202000958; DOI: 10.26508/lsa.202000958
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
Issue Cover

In this Issue

Volume 4, No. 6
June 2021
  • Table of Contents
  • Cover (PDF)
  • About the Cover
  • Masthead (PDF)
Advertisement

Jump to section

  • Article
    • Abstract
    • Introduction
    • Results
    • Discussion
    • Materials and Methods
    • Acknowledgements
    • References
  • Figures & Data
  • Info
  • Metrics
  • Reviewer Comments
  • PDF

Subjects

  • Microbiology, Virology & Host Pathogen Interaction

Related Articles

  • No related articles found.

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • ERK activation blocks ciliary assembly
  • KRAS-mediated (sub)complexes
  • Preference of CAMSAP3 and expansion of microtubule lattice
Show more Research Article

Similar Articles

EMBO Press LogoRockefeller University Press LogoCold Spring Harbor Logo

Content

  • Home
  • Newest Articles
  • Current Issue
  • Archive
  • Subject Collections

For Authors

  • Submit a Manuscript
  • Author Guidelines
  • License, copyright, Fee

Other Services

  • Alerts
  • Twitter
  • RSS Feeds

More Information

  • Editors & Staff
  • Reviewer Guidelines
  • Feedback
  • Licensing and Reuse
  • Privacy Policy

ISSN: 2575-1077
© 2023 Life Science Alliance LLC

Life Science Alliance is registered as a trademark in the U.S. Patent and Trade Mark Office and in the European Union Intellectual Property Office.